
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Puretech Health Plc | LSE:PRTC | London | Ordinary Share | GB00BY2Z0H74 | ORD 1P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
128.40 | 130.00 | 130.80 | 126.00 | 126.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Home Health Care Services | USD 157.6M | USD 53.51M | USD 0.2235 | 5.76 | 304.54M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
16:35:19 | O | 1,121 | 202.00 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
16/6/2025 | 17:27 | UK RNS | PureTech Health PLC Result of AGM |
29/5/2025 | 17:30 | UK RNS | PureTech Health PLC Holding(s) in Company |
22/5/2025 | 12:00 | UK RNS | PureTech Health PLC PRTC to Present at Jefferies Healthcare Conference |
21/5/2025 | 15:17 | ALNC | ![]() |
21/5/2025 | 07:00 | UK RNS | PureTech Health PLC PRTC: IPF Data Support Lung Function Stabilization |
09/5/2025 | 12:00 | UK RNS | PureTech Health PLC PRTC Publishes Research on Unmet IPF Patient Needs |
01/5/2025 | 12:00 | UK RNS | PureTech Health PLC PRTC To Present Ph2b IPF Results at ATS Conference |
30/4/2025 | 14:57 | ALNC | ![]() |
30/4/2025 | 07:32 | ALNC | ![]() |
30/4/2025 | 07:00 | UK RNS | PureTech Health PLC Final Results |
Puretech Health (PRTC) Share Charts1 Year Puretech Health Chart |
|
1 Month Puretech Health Chart |
Intraday Puretech Health Chart |
Date | Time | Title | Posts |
---|---|---|---|
11/6/2025 | 14:46 | PureTech Health - innovative healthcare | 3,149 |
22/7/2018 | 21:35 | PureTech Health (PRTC) One to Watch Monday | - |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
Top Posts |
---|
Posted at 22/6/2025 09:20 by Puretech Health Daily Update Puretech Health Plc is listed in the Home Health Care Services sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech Health was 127.20p.Puretech Health currently has 239,421,312 shares in issue. The market capitalisation of Puretech Health is £308,374,650. Puretech Health has a price to earnings ratio (PE ratio) of 5.76. This morning PRTC shares opened at 126p |
Posted at 30/4/2025 08:27 by the shuffle man The Board recognizes that there remains a disconnect between the value of PureTech's assets and our share price. We are working closely with the CEO and management team to explore all strategic options to address this gap-including recent take-private discussions-with the goal of unlocking value in a manner that is in the best interest of all shareholders. |
Posted at 13/4/2025 22:05 by kingston78 The share price will soon rise to 150 p, possibly this week. |
Posted at 11/4/2025 09:37 by the shuffle man He is just repeating what we already know that there is a big disconnect between value and the share price.If you google how to read articles behind a paywall you can find links that allow you to read these pages. |
Posted at 11/4/2025 07:24 by tsmith2 it's amazing how many times the share price falls while an I is loading up? |
Posted at 10/4/2025 18:24 by hatfullofsky All just noise, BioTechs in general (and BMY specifically) getting hammered again.Clear Mr Market is bucketing PRTC in the same "below cash" group but PRTC have a 3 year run way and 2% royalty deal, not just a pile of cash and a pipe dream. PRTC will report either on or near BMY results around 25/04 and we already know Cobenfy is flying 08/04/25 - www.investing.com/ne In other recent news, Bristol-Myers Squibb’s drug Cobenfy has shown promising prescription growth, with a 9% week-over-week increase reaching 1,573 prescriptions, according to BMO Capital Markets. Analysts at BMO expect Cobenfy to generate approximately $29 million in revenue for the first quarter of 2025, surpassing current consensus estimates by 43%. UBS analysts, maintaining a Neutral rating with a $60 price target, noted a leveling off in prescriptions but still project significant sales for Cobenfy, estimating between $18 million and $21 million for the first quarter. The UBS forecast closely aligns with consensus estimates, suggesting a successful launch compared to similar antipsychotics. $10m revenue for BMS in final 2 months of 2025 1000 prescriptions per week end January 2025 - “launch is really off to a strong start” Trials testing it against Alzheimer’s disease psychosis and as an adjunctive therapy for schizophrenia should produce results this year and next. Farther out, Bristol Myers is planning pivotal studies in Alzheimer’s cognition, bipolar I disorder and irritability caused by Autism spectrum disorder. Risinger and his team have forecast the drug eventually generating close to $8 billion in annual sales. |
Posted at 09/4/2025 16:34 by cool runnings This share price action is frightening ! The management need replacing asap. Rejection of an offer that is muted to be in the region of £2, because they are lining their own pockets and now they are at all time lows trading below cash ! Someone needs to start a process to remove the board and their inept CEO |
Posted at 09/4/2025 11:44 by skyship Totally bizarre price action here. Company stuffed with cash announces an Offer may be in the offing; so the share price plunges 15-20% !!!Got to be a BUY; but failing to see the catch... |
Posted at 08/4/2025 09:05 by ashkv I appreciate PRTC has a bloated Admin Expense nonetheless this share price needs concrete management action ASAP!!!Or this management and complacent board should be replaced!!! |
Posted at 08/4/2025 09:04 by ashkv Bizarre reaction - PRTC Directors / Management should have if permitted by rules released the takeover price that was turned down!!!Very very odd reaction and that a short has appeared on the register when PRTC trading close to net cash. Has UBS come out with their analysis / target price for PRTC post being appointed PRTC's Broker? |
Posted at 07/4/2025 16:50 by the shuffle man The shares trading on the NASDAQ are currently trading at $19 +5% on the day. Can we equate this back to the UK share price. This doesnt seem to be indicating a big premium. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions